The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Hamlet Gasoyan, MD, discussed the implications of a multiple myeloma study’s findings and their potential impact on clinical ...

Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...

Sharda Sinha's battle with Multiple Myeloma highlights the disease's dangers. Learn about its impact and significance.- Watch ...

Approximately every nine minutes, someone in the United States dies from a blood cancer, according to the Leukemia & Lymphoma ...

“MRD negativity is a prognostic marker of prolonged survival outcomes for patients with multiple myeloma. The significantly increased overall and sustained MRD negativity rates reinforce ... 3 ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...

Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.

Multiple myeloma is a type of cancer where plasma cells in bone marrow ... or kidney failure wasn’t associated with a worsened survival rate. Researchers concluded that the development of ...